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in clinical procedures through continuous intrathecal (i.t.) infusion for the treatment of severe chronic pain, including neuropathy. 13 However, ziconotide has a narrow therapeutic window because it produces serious side effects, even at analgesic therapeutic doses. 14, 15 Thus, to improve the quality of pain management, it is necessary to investigate new analgesic agents with reduced adverse side effects and improved clinical efficacy. 4 With this purpose, toxins obtained from the venom of the Brazilian "armed" spider Phoneutria nigriventer have been investigated. [16] [17] [18] Previous studies demonstrated that the preferential NVSCC blocker Phα1β has analgesic effects in rodent chronic and acute pain models, especially from inflammatory origins, with a wider therapeutic index than ω-conotoxin MVIIA. 16, 17, 19 However, until now, the Phα1β antinociceptive and toxic effects have only been evaluated after a single i.t. injection, and ziconotide is clinically used through continuous i.t. infusion. Thus, to further explore the analgesic potential of Phα1β, we evaluated the antinociceptive and toxic effects of Phα1β after single i.t. injection and continuous i.t. infusion in a rat model of neuropathic pain.
METHODS Animals
Adult male Wistar rats (200-300 g) bred in-house were used. Animals were housed in a controlled environment (22°C ± 1°C) with a 12-hour light/dark cycle (lights on 6:00 am to 6:00 pm) and fed standard lab chow and tap water ad libitum. The animals were acclimated to the experimental room for at least 2 hours before the experiments. Each animal was used only once. All protocols were approved by the Institutional Animal Care and Use Committee of the Federal University of Santa Maria (CEUA, process number 086/2011). The number of animals and intensity of noxious stimuli used were the minimum necessary to demonstrate consistent effects of the drug treatments in accordance with current ethical guidelines on the investigation of experimental pain in conscious animals. 20 Behavioral evaluation was performed blindly with respect to drug administration.
Drugs
Native Phα1β was purified from the venom of the Brazilian spider P nigriventer through a combination of gel filtration, reverse-phase fast protein liquid chromatography/fast protein liquid chromatography, and ionexchange high-performance liquid chromatography. 21 The stock solution of Phα1β was prepared in phosphate-buffered saline (PBS; 137 mmol/L NaCl, 2.7 mmol/L KCl, and 10 mmol/L phosphate buffer) in siliconized plastic tubes, maintained at −20°C, and diluted to the desired concentration just before use.
Neuropathic Pain Model
To induce neuropathic pain, the animals were anesthetized with a mixture of ketamine (90 mg/kg) and xylazine (30 mg/kg) through intraperitoneal (i.p.) injection. Chronic constriction injury (CCI) of the sciatic nerve was performed according to the previously described method with minor modifications. 22 Briefly, the sciatic nerve was exposed in the midline of the thigh and close to its trifurcation, where it was held with 3 loose ligatures 1 mm distant from each other using nylon thread (4.0). The incision was closed using a nylon suture (6.0). As a control of the procedure, sham-operated animals were used, in which the sciatic nerve was exposed, but no ligation or injury of the nerve was performed.
Nociception Assessment
Mechanical thresholds in rats were measured as the 50% paw withdrawal threshold (PWT) using the "up-anddown" paradigm as described previously. 23 First, rats were first acclimatized (1 hour) in individual clear Plexiglass boxes (9 × 7 × 11 cm) on an elevated wire mesh platform to allow access to the plantar surface of the hindpaws. Von Frey filaments of increasing stiffness (6, 8, 10, 15, 26, 60 , and 100 g) were applied to the rat's hindpaw plantar surface with a high enough pressure to bend the filament. The absence of paw lifting after 5 seconds led to the use of the next filament with increasing weight, whereas paw lifting indicated a positive response and led to the use of the next weaker filament. This paradigm continued for a total of 6 measurements. The 50% mechanical PWT (50% PWT) response was then calculated from the resulting scores. 24 The 50% PWT was expressed in grams, and it was evaluated before the CCI procedure (baseline values), 8 days after the CCI procedure and before treatments (time point 0), and several time points after the single or continuous administration of Phα1β or vehicle. Nociception was assessed by detecting mechanical hyperalgesia, considering a significant reduction in 50% PWT values after CCI compared with baseline values.
Adverse Effect Assessment
Behavioral adverse effects, such as serpentine-like tail movement and body shaking, were assessed 8 days after the neuropathic pain model was developed (CCI) immediately after and 4 hours after the single i.t. administration of Phα1β (30 or 100 pmol/site). 25 Adverse effects were counted as the proportion of animals that showed any of the abovedescribed adverse effects. 18 
Histopathological Analysis
Seven days after catheter placement, the animals were euthanized with pentobarbital sodium overdose (100 mg/ kg i.p.). Briefly, the animals were perfused with PBS solution containing 4% paraformaldehyde. The spinal cord, brainstem, and encephalon were carefully removed from the group of animals with an osmotic pump and one group without for histopathological analysis. 26, 27 Sections of 0.3μm thickness were stained with hematoxylin and eosin and evaluated (10 images per sample of each animal) in a blinded manner in relation to the treatment of domestic animals by pathologists with extensive experience at the Division of Veterinary Pathology, Federal University of Rio Grande do Sul.
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Single i.t. Administration
First, to observe the antinociceptive effect of Phα1β in a model of neuropathic pain, we administered Phα1β (10, 30, or 100 pmol/site) or vehicle (PBS, 10 μL) through a single i.t. injection in animals that presented nociception 8 days after nerve injury, as previously described. 17 The mechanical threshold of animals was observed before the lesion, before treatment, and 4 hours after treatment for the dose-response curve or from 0.5 to 8 hours after treatment for the time-response curve. Intrathecal injection was performed in accordance with the previously mentioned procedure. 28 Briefly, 10 μL was injected i.t. in bolus in unanesthetized rats using a 28-gauge needle connected to a 10-mL Hamilton microsyringe while the animal was lightly restrained to maintain the position of the needle. Puncture of the dura mater was indicated behaviorally by a slight flick of the tail.
Spinal Catheterization Procedure and Continuous i.t. Infusion
In a different experiment, we delivered Phα1β (60 pmol/μL/h) or vehicle (PBS, 1.0 μL/h) through continuous infusion for 7 days, as previously described. 29 To obtain sustained i.t. drug delivery, a soft polyurethane catheter (Alzet Durect, Cupertino, CA) was inserted through a small hole into the dura at the T1 vertebral level. All animals were anesthetized with a mixture of ketamine (90 mg/kg) and xylazine (30 mg/kg) through i.p. injection. The tip of the catheter was positioned subdurally on the dorsal side of the spinal cord over the center of the injury and reached the L6-S1 spinal cord level. The catheter was tied to the muscles with stitches, and the other end of the catheter was sealed and left subcutaneously. 30 The muscles and skin were sutured. Next, an osmotic pump (Alzet, Cupertino, CA, type 2001) operating at a rate of 1 μL/h for 7 days was filled with Phα1β (60 pmol/μL/h) or PBS (1 μL/h) and attached to the catheter. The osmotic pump was placed between the shoulder blades. The mechanical threshold was measured before injury, before treatment, and once a day after treatment (beginning 24 hours after catheterization). The i.t. catheter was placed 8 days after sham or nerve injury. No animal showed physical changes after the surgical procedure. For histopathological analysis, the animals were euthanized on day 7 after catheter placement.
Statistical Analysis
The results are presented as the means ± SEM. The percentages of maximal inhibition were reported as the mean ± SEM of inhibition obtained in each experiment in relation to the control values. Nociception data were analyzed by Student t test (used to detect the development of mechanical hyperalgesia after nerve injury induction, Results section), 2-way analysis of variance (ANOVA) followed by multiple 2-group t tests with Bonferroni correction of the P values (used to analyze the results are shown in Fig. 1 ), 1-way ANOVA followed by Duncan new multiple range test (used to analyze the results are shown in Fig. 2 ). In addition, the results shown in Figure 3 were analyzed using 2-way ANOVA followed by multiple 2-group t tests with Bonferroni correction of the P values. For analysis of proportions, the c2 test was used to compare each time point (Table 1) or each day of treatment ( Table 2) to compare vehicle versus Phα1β treatment. The level of significance was set at P < 0.05.
RESULTS

Phα1β Produced Antihyperalgesic Effects after Single i.t. Administration in a Model of Neuropathic Pain Without Detectable Side Effects
Nerve injury induction in rats caused pronounced nociception, which was assessed as the appearance of mechanical hyperalgesia (mechanical thresholds decreased from 26.9 ± 2.5 g at baseline to 11.5 ± 1.1 g 8 days after CCI; P < 0.001, Student t test). As expected, the sham-operated animals did not show hypersensitivity to mechanical stimulus (mechanical thresholds 24.1 ± 2.5 g at baseline and 23.2 ± 1.1 g 8 days after CCI; P = 0.44, Student t test). . The data are expressed as the mean ± SEM of mechanical painful hypersensitivity, which was expressed as the 50% mechanical paw withdrawal threshold (PWT in grams, represented in log values). Each point represents the mean ± SEM for 5 to 7 animals. The asterisks denote the significance levels, *P = 0.040; ***P < 0.001 compared with the vehicle-treated group, and #P < 0.001 compared with baseline values (2-way analysis of variance followed by followed by Student 2-group t test with Bonferroni correction).
We observed a reduction in mechanical hyperalgesia from 1 to 6 hours after Phα1β (30 pmol/site; Fig. 1A ), the same result was observed for the dose of 100 pmol/site (data not shown). Moreover, Phα1β administration did not induce any effect per se in the mechanical threshold of sham-operated animals at any time observed (Fig. 1B) . Figure 2A shows the dose-response curve for Phα1β in neuropathic animals 4 hours after treatment. The single i.t. injection of Phα1β at doses of 30 and 100 but not 10 pmol/ site reduced mechanical hyperalgesia (maximal inhibition value of 100% for 30 and 100 pmol/site). In addition, Phα1β i.t. injection did not induce any effect per se in the mechanical threshold of sham-operated animals at any dose tested (Fig. 1B) . Single i.t. Phα1β administration did not induce any observed side effect immediately after injection and for 4 hours after administration (Table 1 ).
Continuous i.t. Phα1β Infusion Showed a Pronounced Antihyperalgesic Effect Not Related to Side Effects or Histopathological Alterations
We observed that continuous i.t. Phα1β (60 pmol/μL/h) infusion for 7 days produced a significant antihyperalgesic effect beginning 24 hours after the initiation of infusion (inhibition of 63% ± 13%) and continuing for 6 more days (90% inhibition on second day and 100% from 3 to 7 days; Fig. 3A ). Moreover, continuous Phα1β treatment in control rats did not induce an effect per se in the mechanical threshold at any time point evaluated (Fig. 3B) . Interestingly, continuous i.t. Phα1β (60 pmol/μL/h) infusion did not induce behavioral side effects ( Table 2) or histopathological changes in diverse central nervous system regions (spinal cord, total encephalon, and brainstem) compared with control animals (vehicle or not infused). The data are expressed as the mean ± SEM of mechanical painful hypersensitivity, which was expressed as the 50% mechanical paw withdrawal threshold (PWT in grams, represented in log values). Each point represents the mean ± SEM of 6 to 7 animals. The asterisks denote the significance levels, **P = 0.008; ***P < 0.001 compared with the vehicle-treated group, and #P < 0.001 compared with baseline values (2-way analysis of variance followed by Student 2-group t test with Bonferroni correction).
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DISCUSSION
Neuropathic pain suggests pathology of the somatosensory system, either in its peripheral elements (peripheral neuropathic pain) or in the central nervous system (central neuropathic pain). 1 A lesion is direct damage to the somatosensory system, while disease refers to indirect injury by metabolic stress, autoimmunity or inflammatory conditions. 1 To evaluate the mechanisms involved in neuropathic pain and develop new therapeutic approaches, different experimental neuropathic pain models have been developed, such as CCI of the sciatic nerve in rodents. 31 We used this experimental approach to neural injury to show the antinociceptive effect of Phα1β after single or continuous i.t. delivery in rats. This peptide was largely able to reduce the mechanical hyperalgesia induced by CCI, and this antinociceptive effect was not related to side effects. Moreover, we evaluated for the first time the unremitting analgesic effect of Phα1β through constant i.t. infusion for 7 days, which did not cause histopathological changes or behavioral adverse effects.
The current pharmacological mainstays of clinical neuropathic pain management are tricyclic antidepressants (amitriptyline) and certain anticonvulsants (gabapentin and pregabalin). 6, 7, 9 However, these drugs are only able to clinically produce 50% of neuropathic pain relief (in 40%-60% of patients) and are also associated with several side effects. 6 However, even with the numerous analgesic drugs available, neuropathic pain is still difficult to treat. 3 A number of voltage-gated and ligand-gated ion channels have been implicated in both normal pain processing and pathological pain. 32 In addition, a significant functional role of NVSCC blockers in neuropathic pain mechanisms has been substantiated by several lines of evidence. [32] [33] [34] [35] In healthy individuals, nociceptive signals from the periphery depolarize subsets of primary afferent fibers, leading to NVSCCs activation at spinal cord terminals, intracellular calcium increment, and neurotransmitter release. 36 Excitatory neurotransmitters (such as glutamate) presynaptically released at the dorsal horn of spinal cord stimulate both interneurons and projecting neurons inducing reflexive withdrawal responses and sending nociceptive information to supraspinal regions involved in pain processing. After nerve injury, it is possible that ion channels (including NVSCCs) could exhibit a gain of function causing spontaneous firing of the primary afferents fibers and depolarization of spinal cord neurons after a non-nociceptive sign. 36 These changes may contribute to pain hypersensitivity in neuropathic pain. 36 This neuronal plasticity in the pain pathway has been widely implicated in spontaneous and evoked pain in neuropathic patients. 37 Thus, the blockade of NVSCCs at the spinal cord is a potential approach to treat neuropathic pain. 29 Currently, numerous toxins isolated from animal venom targeting NVSCC have been tested to treat neuropathic pain. 11, 38 One option for neuropathic pain and cancer management is the ω-conotoxin MVIIA, which was originally isolated from the cone snail C magnus and later synthesized and called ziconotide. 11, 12 Ziconotide has been used in the therapeutic management of neuropathic pain through the i.t. route and produces a marked analgesic effect. It has been also shown that continuous i.t. infusion of ziconotide produced an analgesic effect in preclinical pain models. 13, 39 However, ziconotide has a narrow therapeutic window and produces serious side effects, even at analgesic therapeutic doses. 14 The side effects tend to occur more commonly at higher doses and include nausea, confusion, postural hypotension, allodynia, abnormal gait, urinary retention, and weakness. 14 Thus, to improve the quality of pain management, it is necessary to investigate new analgesic agents with reduced adverse side effects, such as blocking NVSCCs.
The purified peptide Phα1β of the venom extracted from the Brazilian armed spider P nigriventer is a powerful blocker of NVSCCs. Our results showed that Phα1β caused a longlasting antinociceptive effect after single i.t. administration in a model of neuropathic pain without detectable side effects. Previously, Phα1β (30 pmol/site) has been shown to be effective in reducing mechanical hyperalgesia for up to 4 hours in a neuropathic nociception model in mice induced by partial sciatic ligation, without the induction of detectable adverse effects. 17 However, side effects related to acute Phα1β i.t. injection were only observed at higher doses (300 pmol/site), and this finding confirms the good therapeutic window of Phα1β. 17 Previously, another study described that i.t administration of ω-conotoxin MVIIA induced dose-related side effects (including serpentine tail movements and body shaking) in rats. 25 The adverse effects associated with ω-conotoxin MVIIA treatment are usually associated with the inhibition of N-type calcium channels, with a slow onset and offset of action in vitro. 10, 40, 41 In addition, leconotide, a potent blocker of N-type channels that is more specific for sensory compared with sympathetic neuronal calcium channels, showed a better safety profile than ziconotide. 42 Therefore, Phα1β i.t. injection could be safer because of its nonspecificity for N-type channels or possibly through a different method of blocking the channel, or even because of a better specificity for sensory calcium channels. Since all VSCC have important physiological roles in the spinal cord, including painful and motor stimuli transmission, the full blockade of a specific VSCC may not only cause antinociception, but also induce adverse effects. 10, 35 Thus, a very selective N-type and effective VSCC blocker, such as ziconotide, causes a large channel blockade in the spinal cord at therapeutic doses producing analgesia as well as toxic effects. On the contrary, Phα1β is not as selective and effective as ziconotide to block voltage-gated calcium channel (VGCC). Thus, the partial blockade of several VGCC by Phα1β may explain its better safety profile. 43 In fact, Phα1β i.t. single injection did not influence heart rate or mean arterial blood pressure 3 hours after treatment. 16 However, we have not evaluated any effects on micturition after i.t. Phα1β in rats, apart from the blockade of spinal VGCC that may alter the micturition reflex after a single i.t. injection. 44 Thus, further studies must be performed to investigate the effects of Phα1β on micturition and arterial blood pressure after continuous infusion. The antinociceptive effect of single Phα1β i.t. administration was measured in diverse acute and persistent pain models in rodents. 16, 17 Furthermore, the continuous use of analgesic drugs can lead to the development of tolerance and adverse toxic effects, which are not observed after acute administration. 5 We observed that the continuous i.t. infusion of Phα1β for 7 days produced a sustained antinociceptive effect in a chronic pain model in rats. Interestingly, after the third day of i.t. Phα1β delivery, it was able to completely block the mechanical hyperalgesia induced by nerve injury. Moreover, we showed that this effect was not related to toxicity or histopathological alterations of central structures, such as the spinal cord, brainstem, and total encephalon. This finding is important mainly because reversal is more difficult than prevention in the clinical setting. 3 However, it will be of interest to further investigate the possible histopathological alterations produced by Phα1β on other structures (such as sensory ganglions and meninges) as well as its ability to cause apoptosis or glial activation. It is also important to emphasize that our findings showed that Phα1β did not induce analgesic tolerance. 45 Accordingly, we found that continuous Phα1β injection was capable of reversing nerve injury-induced mechanical allodynia. This is an important finding because the available analgesic drugs often have limited therapeutic value in the management of neuropathic pain and they may, in fact, be a risk to patients due to their common side effects. 3 Taken together, our data showed that the armed spider neurotoxin Phα1β effectively alleviates neuropathic pain after single or continuous i.t. delivery without detectable side effects. Collectively, our results hold significant promise that Phα1β could be a novel therapeutic agent to manage symptoms of chronic neuropathic pain by i.t. infusion. E
